Consistent with this, reduced circulating FGF19 levels have been demonstrated in CMD patients [239,240], and systemic FGF19 levels inversely correlate with the atherogenic index and other cardiometabolic traits such as insulin resistance [239,240,241,242,243]. Here, FGF19 is linked to Insulin resistance.